Policy & Regulation
Etcamah–CDK4/6 inhibitor combination approved in US for ESR1-mutated HR-positive breast cancer
7 September 2026 - Biopharmaceutical company AstraZeneca PLC (STO: AZN; LON: AZN; NYSE: AZN) said on Monday that US regulators have granted accelerated approval for Etcamah (camizestrant), its next-ge...
Ionis partner Novartis reports pelacarsen Phase 3 trial misses primary endpoint
7 September 2026 - RNA therapy company Ionis Pharmaceuticals Inc (Nasdaq: IONS) disclosed on Monday that its partner Novartis reported topline results from the Phase 3 Lp(a)HORIZON study and said pela...
Guardant Health wins FDA approval for Guardant360 CDx in advanced breast cancer
7 September 2026 - Precision oncology company Guardant Health Inc (Nasdaq:GH) announced on Friday that the US Food and Drug Administration (FDA) has approved Guardant360 CDx as a companion diagnostic ...
4basebio announces expansion of DNA offering for personalised mRNA medicines
7 September 2026 - Synthetic DNA 4basebio PLC (AIM: 4BB) declared on Monday that it has expanded its DNA offering to support production of critical starting material for personalised mRNA medicines.Th...
Clover Biopharmaceuticals reports positive Phase 2 trial data for respiratory combination vaccine candidates
7 September 2026 - Chinese biotechnology company Clover Biopharmaceuticals Ltd (HKEX:02197) announced on Sunday positive preliminary data from a Phase 2 clinical trial in older adults in Australia eva...
Rznomics reports advances in high-efficiency circRNA production in Nucleic Acids Research
7 September 2026 - Rznomics Inc (KOSDAQ: 476830), a South Korea-based biopharmaceutical company specialising in the development of RNA-based gene therapies, on Monday announced a breakthrough in the h...